Peter Múdrý

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial

Gianni Bisogno, Gian Luca De Salvo, Christophe Bergeron et al. · The Lancet Oncology · 2019 · 231 citations · Full text

Oncology, Metronomic Therapy, Rms 2005 +9

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

Gianni Bisogno, Meriel Jenney, Christophe Bergeron et al. · The Lancet Oncology · 2018 · 182 citations

Oncology, Medicine, Dose-intensified Doxorubicin +10

Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

Daniel Orbach, Bernadette Brennan, Angela De Paoli et al. · European Journal of Cancer · 2016 · 122 citations

Infantile Fibrosarcoma, Conservative Strategy, Pediatrics +1

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

Danica Zapletalová, Nicolás André, L. Deak et al. · Oncology · 2012 · 85 citations

Outcome of extracranial malignant rhabdoid tumours in children registered in the European Paediatric Soft Tissue Sarcoma Study Group Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study—EpSSG NRSTS 2005

Bernadette Brennan, Gian Luca De Salvo, Daniel Orbach et al. · European Journal of Cancer · 2016 · 81 citations

Surgical Oncology, Pediatric Brain Tumors, Medicine +4